Pham Son V, Chilton Robert
The University of Texas Health Science Center, San Antonio, Tex.
The University of Texas Health Science Center, San Antonio, Tex.
Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006.
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.
心脏病专家可以将恩格列净视为一种心血管药物，它对降低2型糖尿病（T2DM）患者的高血糖也有有益作用。在最近的2型糖尿病患者心血管结局事件试验——去除多余葡萄糖（EMPA-REG OUTCOME）试验中，恩格列净降低T2DM高心血管风险患者心血管死亡和因心力衰竭住院风险的作用，主要可以从心血管生理学的变化来解释；也就是说，恩格列净可能通过降低血压、改善主动脉顺应性和改善心室动脉耦联来减轻心脏负荷和心肌氧消耗。本报告将讨论这些概念和假说。
